Chargement des cours...
Prévisions
| Acheter |
1 |
| Conserver |
1 |
| Vendre |
0 |
Actualités Accéder au fil d'actualités
Allarity Therapeutics receives CLIA certification for its laboratory in Denmark
Allarity Therapeutics has received a CLIA registration certificate for its laboratory in Hørsholm, Denmark, enabling DRP® biomarker tests to be conducted internally for US-approved clinical trials. The certification is expected to shorten turnaround times, reduce long-term costs by cutting outsourcing, and support development of lead candidate Stenoparib for advanced, platinum-resistant ovarian cancer. The lab will also be able to offer DRP and laboratory services to third parties. At the same time, the company faces high cash burn; market capitalization is around $19 million and free cash flow was recently negative. » Plus sur de.investing.com
Données financières de l'entreprise
| (EUR) | juin 2026 | |
|---|---|---|
| Chiffre d'affaires | 0 | - |
| Bénéfice brut | 0 | - |
| Bénéfice net | -2,98 M | 51,57 % |
| EBITDA | -2,14 M | 9,71 % |
Données fondamentales
| Indicateur | Valeur |
|---|---|
Capitalisation boursière | 19,44 M € |
Nombre d'actions | 15,91 M |
Plus haut/bas sur 52 semaines | 1,77 € - 0,66 € |
| Dividendes | Non |
Bêta | 0,56 |
Ratio P/E | -1,82 |
Ratio PEG | -0,01 |
Ratio P/B | 6,39 |
Ratio P/S | 65,49 |
Profil de l'entreprise
| Nom | Allarity Therapeutics Aktie |
| PDG | Thomas H. Jensen |
| Employés | 8 |
Découvrir des actifs
Les actionnaires de Allarity Therapeutics Aktie investissent également dans les actifs suivants
